

(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Date: August 11, 2023

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir,

Sub: Outcome of board meeting held on today i.e. on, August 11, 2023, in terms of second proviso to Regulation 30(6) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on Friday, August 11, 2023, at the Registered Office of the Company situated at Plot No. PF-21, Nr. Acme Pharma, Opp. Teva Pharma Sanand GIDC-II, Sanand Ahmedabad-382110, which was commenced at 04:15 P.M. and concluded at 05:15 P.M., to have;

1. Considered, approved and taken on record the Unaudited Standalone and Consolidated financial result of the Company for the quarter ended on June 30, 2023.
2. Approved the Limited Review Report issued by Statutory Auditors of the Company for the Quarter ended on June 30, 2023.
3. Approved Draft Directors report of the company for the financial year 2022-23.
4. Decided to call the 8th Annual General Meeting of the Company on Monday, September 11, 2023, at 04:00 P.M. (IST) through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") in compliance with the applicable circulars of Ministry of Corporate Affairs (MCA).

The copy of Notice of 8th Annual General Meeting and Annual Report for the financial year 2022-23 will be submitted to exchange as soon as the same be dispatched to the Shareholders of the Company through e-mail registered with Company/Depositories.

5. Approved Schedule of Annual General Meeting w.r.t cutoff date for remote e-voting, remote e-voting start date and end date.
6. Appointment of National Securities Depository Limited (NSDL) as Remote E-Voting Agency for resolutions proposed to be passed at Annual General Meeting.
7. Approved Appointment of M/s. SCS and CO LLP, Practicing Company Secretary as Scrutinizer for E-Voting Process for AGM.
8. Approved Appointment of M/s. Suthar Haresh & Associates, Cost Accountants, as Cost Auditors for the financial year 2023-24. (Brief Profile of Cost Auditors is enclosed herewith as Annexure I.)



(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

9. Pursuant to the recommendation of the Audit Committee, the Board of Directors of the company has considered and approved the appointment of M/s. Keyur Shah & Co., Chartered Accountants (FRN: 141173W), Ahmedabad as Statutory Auditors of the Company for a First term of Four consecutive years commencing from the conclusion of the 8th Annual General meeting to be held on September 11, 2023 till the conclusion of the 12th AGM of the Company.

The details required under SEBI (LODR) Regulation, 2015 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 attached as per Annexure II.

10. On recommendation of Nomination & Remuneration Committee, appointed Ms. Niyati Dipesh Parikh (Membership No. F12289) as Company Secretary & Compliance Officer of the Company w.e.f. August 11, 2023.

The details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is given in the enclosed Annexure III.


11. Considered and approved all other business as per agenda circulated.

Kindly take the same on your record and oblige us.

Thanking you.

Yours faithfully,

For, Sotac Pharmaceuticals Limited



Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad



(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Annexure I

Details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Appointment of Cost Auditors:

Sr. No.	Details of the event that need to be provided	Information of Such events
1.	Name of the Cost Auditor	M/s. Suthar Haresh & Associates, Cost Accountants (FRN: 002124).
2.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment as Cost Auditors of the Company.
3.	Date of appointment/ cessation & term of appointment	August 11, 2023 For Conducting Cost Audit of the Company for the Financial year 2023-24.
4.	Brief Profile;	Suthar Haresh & Associates, Cost Accountants, having its offices at Ashram Road, Ahmedabad, is providing its highly professional services in the areas of Cost Audit, Cost Compliance, Indirect Taxation, Financial and Legal Consulting. The core management of the firm includes CMA Haresh Suthar as Proprietor. They have a team of highly qualified professionals having rich experience of more than five years in providing Cost Audit & Compliance, Product Costing and other required fields. They provides Services of; 1. Statutory Cost Accountant Services: Such as Internal audit (general operations or production specific), Preparation and guidance for cost records required under law etc. 2. Cost Consultancy Services: Such as Variance Analysis, Pricing Decisions, Asset Efficiency, Replacement Analysis, Product Mix - Review and Ascertain Best Product Mix, Designing XLS Template for Price Quotation etc. 3. Other Professional Services: Such as Budgeting and Budgetary Controls with special focus on profit management, Stock / Asset Audit – Physical Verification, Develop tailor-made MIS for Best Decision Making etc.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
6.	Information as required pursuant to NSE Circular with Ref No. NSE/CML/2018/24 dated June 20, 2018	-



(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Annexure II

Details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Appointment of Statutory Auditors:

Sr. No.	Particulars	Details
1.	Name of the Company	Sotac Pharmaceuticals Limited
2.	Name of Auditor	M/s. Keyur Shah & Co., Chartered Accountants (FRN: 141173W), Ahmedabad.
3.	Reason for Change viz., appointment, resignation, removal, death or otherwise	Appointment as Statutory Auditors at 8 th Annual General meeting to be held on September 11, 2023.
4.	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment / re-appointment	Appointment of M/s. Keyur Shah & Co., Chartered Accountants (FRN: 141173W), Ahmedabad as Statutory Auditors of the Company for a First term of Four consecutive years commencing from the conclusion of the 08th Annual General meeting to be held on September 11, 2023 till the conclusion of the 12th AGM of the Company. Which shall be subject to approval of Shareholder at the ensuing Annual General Meeting of the Company.
5.	Brief profile	<p>Keyur Shah & Co. is a professionally managed Chartered Accountants Firm having its offices in Ahmedabad, Gujarat. The firm was founded by Mr. Keyur Shah, he brings a wealth of experience spanning over 12 years in various domains such as capital markets, project funding, direct tax, business advisory, tax advisory, and business valuations. With his expertise, he has become an FAFD (Forensic Audit and Fraud Detection) certified professional.</p> <p>Keyur Shah & Co. has a dedicated professionals collaborated to provide Project Finance, Audit, Consulting, Financial & Corporate Advisory, Fund Raising, Capital Market, Wealth Management, Tax, Legal and Related Services to Clients.</p> <p>An One Stop Single Window Advisory Firm offering Integrated Business, Legal and Financial Solutions to varied sections of society including SMEs and Large Corporate Enterprises. The firm is committed to providing high-quality, ethical services to its clients.</p>
6.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
7.	Information as required pursuant to NSE Circular with Ref No. NSE/CML/2018/24 dated June 20, 2018	-



(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Annexure III

Details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Name of Key Managerial Personnel: Ms. Niyati Dipesh Parikh

Sr.No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment
2.	Name and Date of Birth	Ms. Niyati Dipesh Parikh
3.	Date of appointment and Term of appointment	Date of Appointment: August 11, 2023. Term of Appointment: Appointed as Company Secretary & Compliance Officer of the Company.
4.	Education Qualification	Company Secretary (C.S.), B.com, LLB
5.	Brief Profile	Ms. Niyati Parikh is a Fellow Member of the Institute of Company Secretaries of India with a Bachelor Degree in Commerce and Bachelor Degree in Law. She has behind her a work experience of 6 years as a Company Secretary and Compliance officer. Her varied areas of knowledge includes Corporate laws, Secretarial Management guidance, Due Diligence, Compliance Audit, Corporate Governance Audit, Merger – Acquisition, FEMA and other Economic Laws.
6.	Disclosure of relationships between directors (In case of appointment of Director)	Not Applicable

SOTAC PHARMACEUTICALS LIMITED

(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451



Date: August 11, 2023

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir,

Sub: Submission of Unaudited Standalone and Consolidated Financial Result of the Company for the quarter ended on June 30, 2023 along with Limited Review Report.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)


In reference to captioned subject and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter ended on June 30, 2023 along with Limited Review Report issued by Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results for the Quarter ended on June 30, 2023.

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Sotac Pharmaceuticals Limited



Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

Contact No.: 99135 62852, 87994 83159, 99250 45971



www.sotacpharma.com



sotacpharma@gmail.com



Limited Review Report on unaudited standalone financial results of Sotac Pharmaceutical Limited for the Quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors Of,
Sotac Pharmaceutical Limited
(Formerly Known As Sotac Pharmaceutical Private Limited)

We have reviewed the accompanying the statement of unaudited Standalone financial results ("the financial statement") of **Sotac Pharmaceutical Limited** ("the Company") for the Quarter ended on June 30, 2023. The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down as per accounting standard prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results, prepared in accordance with applicable standards and other recognized accounting practices and policies has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Co.
Chartered Accountants
F.R. No. 141173W

Keyur Shah
Proprietor
M. No. 153774
UDIN: - 23153774BGWLXW5127



Date: - 11th August, 2023
Place: - Ahmedabad

SOTAC PHARMACEUTICALS LIMITED
(Formerly known as Sotac Pharmaceuticals Private Limited)
Plot No PF-20, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110
STANDALONE STATEMENT OF UNAUDITED FINANCIAL RESULT FOR THE QUARTER ENDED JUNE 30, 2023

(INR in Lakhs unless otherwise Specified)

Sr no.	Particulars	Quarter ended		Year ended	
		30.06.2023 Unaudited	31.03.2023 Audited	30.06.2022 Unaudited	31.03.2023 Audited
I)	REVENUE FROM OPERATIONS	1891.05	1317.82	1504.72	5798.28
II)	OTHER INCOME	23.15	12.53	6.76	24.31
III)	TOTAL REVENUE (I + II)	1914.20	1330.35	1511.48	5822.59
IV)	EXPENSES				
a)	Cost of Material Consumed	1199.35	1090.51	1010.69	4272.34
b)	Purchase of Stock-in-Trade	7.73	18.15	7.83	52.64
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	66.36	(300.09)	8.01	(318.38)
d)	Employee Benefit Expenses	72.27	73.49	63.53	292.67
e)	Finance Costs	34.20	30.55	17.23	86.13
f)	Depreciation and Amortisation Expense	46.27	45.46	33.60	162.53
g)	Other Expenses	319.38	197.62	122.04	678.21
	TOTAL EXPENSES (IV)	1745.56	1155.69	1262.93	5226.14
V)	PROFIT/(LOSS) BEFORE EXCEPTIONAL & EXTRAORDINARY ITEMS & TAX (III - IV)	168.64	174.66	248.55	596.45
VI)	Exceptional/Prior Period Items	-	-	-	-
VII)	PROFIT BEFORE EXTRAORDINARY ITEMS & TAX (V-VI)	168.64	174.66	248.55	596.45
VIII)	Extraordinary Items	-	-	-	-
IX)	PROFIT BEFORE TAX (VII-VIII)	168.64	174.66	248.55	596.45
X)	TAX EXPENSE				
a)	Current Tax	45.63	48.87	70.08	168.39
b)	Deferred Tax	2.48	2.41	(7.11)	(21.49)
	TOTAL TAX EXPENSE (X)	48.11	51.28	62.97	146.90
XI)	PROFIT / (LOSS) FOR THE PERIOD/YEAR (IX-X)	120.53	123.38	185.58	449.55
XII)	Paidup Equity Share Capital (Face value Rs 10 each)	1105.00	805.00	230.00	805.00
XIII)	Reserve & Surplus (Excluding Revaluation Reserve)				346.98
XIII)	EARNINGS PER EQUITY SHARE-BASIC/DILUTED				
	Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended)	1.12	1.53	8.07	5.58

Notes:

- [1] The standalone unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable
- [2] The above standalone unaudited financial results for the quarter ended June 30, 2023 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 11, 2023. A limited review of the above results has been carried out by the statutory auditors of the company
- [3] The figures for the quarter ended 31 March 2023 are the Balancing figures between the audited figures in respect of full financial year and the year-to-date figures up to the third quarter ended on 31 december 2022 which are subject to limited review.
- [4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary.
- [5] The Company has Voluntarily adopted the quarterly standalone unaudited financial results for the quarter ended 30th June 2023.
- [6] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.
- [7] The company had made an initial public offering (IPO) of 30,00,000 equity shares of face value of Rs. 10/- each fully paid up for cash at a price of Rs. 111/- per equity share (including share premium of Rs. 101 per equity share) aggregating to Rs.3330.00/- Lakhs. The aforementioned equity shares of the company allotted as on 10th April, 2023 and got listed on NSE Emerge Platform on 13th April, 2023.
- [8] The Status of investor's complaints during the year ended on June 30, 2023 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	1
Complaints disposed during the period	1
Complaints resolved at the end of the period	Nil

- [9] The Proceeds from the IPO before Net off Issue related expenses is RS. 3,330.00 Lakhs. The Object for the are as follows:

Sr. No.	Particulars	Planned As per Prospectus	Utilised	Pending to be Utilised
a	To Meet Working Capital Requirements	1,080.00	1,080.00	Nil
b	Investment in Subsidiary	700.00	700.00	Nil
c	Upgradation / Construction of Existing /New Building in the Existing Premises	590.01	590.01	Nil
d	General Corporate Purpose	739.99	739.99	Nil
e	Public Issue Expenses	220.00	220.00	Nil
	Total	3,330.00	3,330.00	Nil



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel

Sharad Patel
DIN:07252252
Chairman & Managing Director

Place : Ahmedabad
Date : 11th August, 2023



Limited Review Report on unaudited consolidated financial results of Sotac Pharmaceutical Limited for the Quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors of,
Sotac Pharmaceutical Limited
(Formerly Known As Sotac Pharmaceutical Private Limited)

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ("the Statement") of **Sotac Pharmaceutical Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2023, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down as per Accounting Standards, Prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Sotac Pharmaceutical Limited ("Parent")
2. Sotac Healthcare Private Limited ("Subsidiary")
3. Sotac Lifesciences Private Limited ("Subsidiary")
4. Sotac Research Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in above and based on the statement provided by the Management related to Parent & Subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of



Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial statements / financial information / financial results of Subsidiaries i.e. Sotac Healthcare Private Limited ("Subsidiary")/ Sotac Lifesciences Private Limited ("Subsidiary")/ Sotac Research Private Limited ("Subsidiary") included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 101.89 Lakhs and total net profit/(loss) after tax of Rs. (22.16) Lakhs for the quarter ended June 30, 2023, respectively, as considered in the consolidated unaudited financial results have not been reviewed by us. These interim financial statements / financial information / financial results have been reviewed by the Auditor of respective subsidiary company and provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports provided by the Management and the procedures performed by us as stated in above paragraph.

Our conclusion on the statement is not modified in respect of the above matters.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W



Keyur Shah
Proprietor

M. No. 153774

UDIN: -23153774BGWLXX1531



Date: - 11th August, 2023

Place: - Ahmedabad

SOTAC PHARMACEUTICALS LIMITED
(Formerly known as Sotac Pharmaceuticals Private Limited)
Plot No PF-20, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110
CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULT FOR THE QUARTER ENDED JUNE 30, 2023

(INR in Lakhs unless otherwise Specified)

Sr no.	Particulars	Quarter ended			Year ended
		30.06.2023 Unaudited	31.03.2023 Audited	30.06.2022 Unaudited	31.03.2023 Audited
I)	REVENUE FROM OPERATIONS	2496.70	1808.39	1986.96	7748.32
II)	OTHER INCOME	22.99	13.62	6.93	34.96
III)	TOTAL REVENUE (I + II)	2519.69	1822.01	1993.89	7783.28
IV)	EXPENSES				
a)	Cost of Material Consumed	1787.67	1473.34	1605.43	6115.23
b)	Purchase of Stock-in-Trade	8.05	13.00	2.32	52.64
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	(26.16)	(291.88)	(61.59)	(440.96)
d)	Employee Benefit Expenses	97.78	112.39	88.39	422.70
e)	Finance Costs	45.82	64.10	29.47	197.55
f)	Depreciation and Amortisation Expense	60.44	60.62	49.96	227.78
g)	Other Expenses	395.77	259.73	160.74	873.69
	TOTAL EXPENSES (IV)	2369.37	1691.30	1874.72	7448.64
V)	PROFIT/(LOSS) BEFORE EXCEPTIONAL & EXTRAORDINARY ITEMS & TAX (III - IV)	150.32	130.71	119.17	334.64
VI)	Exceptional/Prior Period Items	-	-	-	58.02
VII)	PROFIT BEFORE EXTRAORDINARY ITEMS & TAX (V-VI)	150.32	130.71	119.17	392.66
VIII)	Extraordinary Items	-	-	-	-
IX)	PROFIT BEFORE TAX (VII-VIII)	150.32	130.71	119.17	392.66
X)	TAX EXPENSE				
a)	Current Tax	45.92	48.87	70.08	168.39
b)	Deferred Tax	6.00	(21.73)	(4.57)	(4.33)
	TOTAL TAX EXPENSE (X)	51.92	27.14	65.51	164.05
XI)	PROFIT / (LOSS) FOR THE PERIOD/YEAR (IX-X)	98.40	103.57	53.66	228.60
XII)	Paidup Equity Share Capital (Face value Rs 10 each)	1105.00	805.00	230.00	805.00
XIII)	Reserve & Surplus (Excluding Revaluation Reserve)				193.88
XIV)	EARNINGS PER EQUITY SHARE-BASIC/DILUTED				
	Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended)	0.92	1.29	2.33	2.84

Notes:

- [1] The consolidated unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable
- [2] The above consolidated unaudited financial results for the quarter ended June 30, 2023 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 11, 2023. A limited review of the above results has been carried out by the statutory auditors of the company.
- [3] The figures for the quarter ended 31 March 2023 are the Balancing figures between the audited figures in respect of full financial year and the year-to-date figures up to the third quarter ended on 31 december 2022 which are subject to limited review.
- [4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary.
- [5] The Company has Voluntarily adopted the quarterly consolidated unaudited financial results for the quarter ended 30th June 2023.
- [6] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.
- [7] The Holding company had made an initial public offering (IPO) of 30,00,000 equity shares of face value of Rs. 10/- each fully paid up for cash at a price of Rs. 111/- per equity share (including share premium of Rs. 101 per equity share) aggregating to Rs.3330.00/- Lakhs. The aforementioned equity shares of the company allotted as on 10th April, 2023 and got listed on NSE Emerge Platform on 13th April, 2023.
- [8] The Sotac Lifesciences Private Limited "The Subsidiary" of the Holding company had made Right Issue of 99,50,000 equity shares of face value of Rs. 10/- each fully paid up for cash at a price of Rs. 10/- per equity share (Security Premium- NIL) aggregating to Rs.99.50/- Lakhs. The abovementioned right equity share allotted as on 11th May, 2023.
- [9] The Status of investor's complaints during the year ended on June 30, 2023 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	1
Complaints disposed during the period	1
Complaints resolved at the end of the period	Nil

- [10] List of the Entities Consolidated in the Statement:

Name of the Subsidiaries Companies	Relationship	% of Holding as on 30-06-2023	Voting Power Either Directly or Indirectly through Subsidiaries
Sotac Healthcare Private Limited	Subsidiary	71.00	Directly
Sotac Research Private Limited	Subsidiary	100.00	Directly
Sotac Lifesciences Private Limited	Subsidiary	51.26	Directly

- [11] The Proceeds from the IPO before Net off Issue related expenses is RS. 3,330.00 Lakhs. The Object for the are as follows:

Sr. No.	Particulars	Planned As per Prospectus	Utilised	Pending to be Utilised
a	To Meet Working Capital Requirements	1,080.00	1,080.00	Nil
b	Investment in Subsidiary	700.00	700.00	Nil
c	Upgradation / Construction of Existing /New Building in the Existing Premises	590.01	590.01	Nil
d	General Corporate Purpose	739.99	739.99	Nil
e	Public Issue Expenses	220.00	220.00	Nil
	Total	3,330.00	3,330.00	Nil



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel
Sharad Patel
DIN:07252252
Chairman & Managing Director

Place : Ahmedabad
Date : 11th August, 2023